Questions about authorisation of alteplase for ischaemic stroke

The Lancet

Volumn 384, Issue 9944, 2014, Pages 659-660

  Shinton, Roger ^a  

^a Hampton in Arden ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO;

BRAIN ISCHEMIA; DRUG APPROVAL; DRUG EFFICACY; DRUG LEGISLATION; FIBRINOLYTIC THERAPY; HUMAN; KAPLAN MEIER METHOD; LETTER; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECALL BIAS; RISK BENEFIT ANALYSIS; STROKE PATIENT; BLOOD PRESSURE; NATIONAL HEALTH ORGANIZATION; PHYSICIAN; PROGNOSIS; STATISTICAL ANALYSIS; SURVIVAL RATE;

BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84906706030     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61385-4     Document Type: Letter

References (12)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1995 1581 1587
2. M O'Fallon, K Asplund, LR Goldfrank et al. Report of the t-PA Review Committee http://stroke.nih.gov/resources/t-pa-review-committee.htm 2004 (accessed June 10, 2014).
3. JR Hoffman, DL Schriger A graphic reanalysis of the NINDS trial Ann Emerg Med 54 2009 329 336
4. JM Wardlaw, V Murray, E Berge, GJ Del Zoppo Thrombolysis for acute ischaemic stroke Cochrane Database Syst Rev 4 2009 CD000213.
5. W Hacke, M Kaste, E Bluhmki for the European Cooperative Acute Stroke Study (ECASS) investigators Alteplase compared with placebo within 3 to 4.5 hours for acute ischemic stroke N Engl J Med 359 2008 1317 1329
6. ATLANTIS The ECASS NINDS rt-PA Study Group Investigators Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials Lancet 363 2004 768 774
7. KR Lees, E Bluhmki, R von Kummer for the ECASS ATLANTIS NINDS and EPITHET rt-PA Study Group Investigators Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials Lancet 375 2010 1695 1703
8. N Wahlgren, N Ahmed, A Davalos et al. Thrombolysis with alteplase 3-4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study Lancet 372 2008 1303 1309
9. KB Slot, E Berge, P Dorman, S Lewis, M Dennis, P Sandercock the Oxfordshire Community Stroke Project the International Stroke Trial (UK) and the Lothian Stroke Register Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies BMJ 336 2008 376 379
10. The IST-3 collaborative group The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (IST-3): a randomised controlled trial Lancet 379 2012 2352 2363
11. The IST-3 collaborative group Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial Lancet Neurol 12 2013 768 776
12. P Sandercock, R Lindley, J Wardlaw, W Whiteley, G Murray the IST-3 collaborative group Statistical analysis plan for the third International Stroke Trial (IST-3); part of a 'thread' of reports of the trial Int J Stroke 7 2012 186 187